礼来Jaypirca在治疗初治CLL/SLL患者中显著改善无进展生存期

投资观察
Sep 08

礼来公司宣布,其Jaypirca(pirtobrutinib)作为首个也是唯一获批的非共价(可逆)BTK抑制剂,在治疗初治CLL/SLL患者中显著改善了无进展生存期。

礼来公司表示,Jaypirca在CLL/SLL治疗中改善了无进展生存期。3期研究结果显示,pirtobrutinib带来了显著改善。

此外,总生存期数据呈现出有利于pirtobrutinib的趋势。在BRUIN CLL-313研究中,pirtobrutinib的安全性特征与之前的试验保持一致。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10